Cancers MDPI’s Post

#MantleCellLymphoma, both in its classical and leukemic, non-nodal forms, is an important differential diagnosis for patients with CD5-expressing lymphomas. How do you differentiate #MCL in patients with CD5-expressing lymphomas?

We're excited to announce that GC Cell has received #MFDS clearance for the #IND of our Phase I trial of #GCC2005, an allogenic anti-CD5 CAR-NK therapy targeting T-cell malignancies. #GCC2005 aims to overcome key challenges of current CAR-T therapies, such as fratricide and T-Cell Aplasia, while offering improved durability and efficacy. This could provide broader and more affordable treatment options for various lymphoma subtypes. With IND clearance, we will begin a Phase I trial this year to assess the safety, tolerability, and preliminary efficacy of #GCC2005 in combination with lymph node chemotherapy for patients with recurrent or refractory T-Cell malignancies. #NavigatingtheFuture #ForEachandEveryPatient #clinicaltrial #IND #MFDS #Tcellmalignancy #CD5 #celltherapy #CAR_NK #TCell #Lymphoma #CGT

In our library of Positive Quality Interventions (PQIs) - precise and concise peer-reviewed clinical guidance resources - you’ll find the 'Initiating Mosunetuzumab-axgb in Relapsed/Refractory Follicular Lymphoma' PQI. This resource provides insights on bispecific T-cell engagement, patient selection, and preventing adverse events during administration in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy. Click the link below to enhance your clinical knowledge: https://bit.ly/492LRJv

🔬 FDA has approved Breyanzi®, a CAR-T therapy for treating adult patients with relapsed or refractory mantle cell lymphoma. This marks the fourth distinct subtype of non-Hodgkin lymphoma that Bristol Myers Squibb’s Breyanzi® can treat, making it the broadest CAR-T cell therapy available for B-cell malignancies. Responses were observed in 85.3% of patients with a one-time infusion while maintaining a consistent safety profile in clinical trials. This highlights the potential of Breyanzi® to offer long-lasting responses for patients with few treatment alternatives. With the rising number of CAR-T therapy approvals, it's vital that these treatments are accessible and affordable for everyone, ensuring widespread patient access to these life-changing therapies. Book a demo to learn how IRO® can help scale the production and delivery of advanced therapies ➡️ https://lnkd.in/eXEXEGZZ Read more: https://lnkd.in/eMq-Vp8j #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

✅Accelerated approval to lisocabtagene maraleucel for adults with relapsed or refractory follicular lymphoma. The recommended lisocabtagene maraleucel dose is 90 to 110 × 106 CAR-positive viable T cells with a 1:1 ratio of CD4 & CD8 components. READ➡️https://lnkd.in/eAFyJJ5x

https://lnkd.in/g_6ieFDB A large retrospective analysis of data from 582 r/r LBCL patients treated with anti-CD19 CAR-T between 2015 and 2022. The frequency of T-cell lymphoma after CAR-T treatment is low (1/549). No conclusive connection is made between T-cell neoplasm development and anti-CD19 CAR-T treatment.

Did you know...? 40-65% of all peripheral T-cell lymphoma (PTCL) cases are associated with the Epstein-Barr Virus (EBV). EBV-positive PTCL cases are typically faster-progressing and more aggressive than those not associated with EBV. #EBV #lymphomaawareness

Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells https://lnkd.in/gDT--KjC

In this nonrandomized controlled trial, response-adapted ultralow-dose therapy for indolent orbital B-cell lymphoma resulted in reduced radiation exposure, negligible toxic effects, and excellent disease outcomes. https://ja.ma/4cYx98m

In this nonrandomized controlled trial, response-adapted ultralow-dose therapy for indolent orbital B-cell lymphoma resulted in reduced radiation exposure, negligible toxic effects, and excellent disease outcomes. https://ja.ma/4eA6MpI